Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752988 | 1.00 | MAPT (0.45) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL16262194 | 0.78 | SIRT6 (0.54) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL16262196 | 0.78 | SIRT6 (0.54) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL16752979 | 0.78 | MAPT (0.55) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL3621737 | 0.77 | MAPT (0.43) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL3621735 | 0.77 | MAPT (0.43) | MAPTALDH1A1DCTPP1LMNASMN1; SMN2 | |
| SCHEMBL215925 | 0.77 | HPGD (0.68) | MAPTALDH1A1DCTPP1SIRT6L3MBTL1 | |
| SCHEMBL215924 | 0.77 | HPGD (0.68) | MAPTALDH1A1DCTPP1SIRT6L3MBTL1 | |
| SCHEMBL3616153 | 0.76 | MAPK1 (0.74) | MAPTALDH1A1DCTPP1SIRT6HTT | |
| SCHEMBL3616157 | 0.76 | MAPK1 (0.74) | MAPTALDH1A1DCTPP1SIRT6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2883875-B1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2016-12-28 | — | — | EP | disclosed |
| US-9199944-B2 | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-2883875-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | Korea Reserach Institute Of Chemical Technology (KR) | 2015-06-17 | — | — | EP | disclosed |
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | PINOTBIO, INC. (KR) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152069-A1 | N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | TNK2, NPM1, NEK4 | MAPT 2670/4885ALDH1A1 3246/4885DCTPP1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.